Agilent Technologies acquired Avida Biomed, a transaction completed in January 2023.
Avida Biomed operates in Diagnostics and Genomics, is based in Fremont, California, USA. Avida Biomed is an early-stage life-sciences company that develops high-performance NGS target-enrichment workflows enabling simultaneous genomic and epigenomic (DNA-methylation) profiling from a single sample, compatible with automation platforms such as Magnis and Bravo.
Avida Biomed complements Agilent's SureSelect target-enrichment portfolio and advances its push into high-growth clinical-research and diagnostics markets for precision oncology.
The team of talented scientists and genomics industry veterans at Avida Biomed have created a best-in-class toolset.Sam Raha, President, Agilent Diagnostics and Genomics Group
Advisory firms were not disclosed for this transaction.